Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 33,200,460 shares, an increase of 34.8% from the January 29th total of 24,620,718 shares. Based on an average daily volume of 8,624,264 shares, the short-interest ratio is currently 3.8 days. Currently, 10.3% of the shares of the company are short sold. Currently, 10.3% of the shares of the company are short sold. Based on an average daily volume of 8,624,264 shares, the short-interest ratio is currently 3.8 days.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP boosted its stake in Sangamo Therapeutics by 63.1% in the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after buying an additional 1,417,029 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Sangamo Therapeutics by 23.7% in the 4th quarter. Invesco Ltd. now owns 1,000,292 shares of the biopharmaceutical company’s stock valued at $420,000 after purchasing an additional 191,561 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $56,000. R Squared Ltd grew its holdings in shares of Sangamo Therapeutics by 22.2% during the 4th quarter. R Squared Ltd now owns 147,191 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 26,732 shares during the last quarter. Finally, Meritage Portfolio Management increased its position in Sangamo Therapeutics by 28.2% during the 4th quarter. Meritage Portfolio Management now owns 227,000 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Price Performance

SGMO traded down $0.00 on Monday, hitting $0.43. 2,091,832 shares of the stock were exchanged, compared to its average volume of 6,523,579. The firm has a market capitalization of $144.35 million, a price-to-earnings ratio of -0.96 and a beta of 1.33. Sangamo Therapeutics has a 12 month low of $0.35 and a 12 month high of $1.06. The business has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.50.

Analyst Ratings Changes

SGMO has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, February 10th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Hold” and an average price target of $4.33.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.